Thomas Gad
CHIEF BUSINESS OFFICER · Y-mAbs Therapeutics, Inc.
Individual
- 2025
- Sep 16, 2025
- 1
Filings (90d)
Other insiders active in the same sector
No other insider has filed at Thomas Gad's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- James E. Flynn - $70.87M in NUVL purchases and sales in the last 12 months
- RA CAPITAL MANAGEMENT, L.P. - $69.43M in VOR purchases and sales in the last 12 months
- Joaquin Duato - $66.84M in JNJ purchases and sales in the last 12 months
- Eric Venker - $65.62M in ROIV purchases and sales in the last 12 months
- EcoR1 Capital, LLC - $65.00M in TRAX purchases and sales in the last 12 months
- Forbion Growth Opportunities Fund III Cooperatief U.A. - $64.80M in BRVE purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Thomas Gad?
Thomas Gad is a corporate insider, tracked as CHIEF BUSINESS OFFICER of Y-mAbs Therapeutics, Inc. (YMAB). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Thomas Gad last file a Form 4?
The only primary Form 4 on record is dated 16 September 2025.
